Key Takeaways
- • Apollo Global Management acquires a minority stake in Bayer's long-acting reversible contraceptives business for €3bn, valuing the unit at approximately $6.5bn based on analyst estimates.
- • The contraceptives portfolio—housing brands including Mirena, Kyleena, and Jaydess—generated €1.4bn in revenue during 2025, with Bayer retaining full operational control of the business.
- • The transaction demonstrates Apollo's shift toward providing bespoke capital solutions and strategic financing to large multinational corporations rather than pursuing traditional leveraged buyouts.
- • Bayer's divestment is part of a broader balance sheet strengthening strategy to manage Roundup litigation liabilities (€11.8bn in provisions) and upcoming debt maturities, supported by an $8bn bank financing facility.
- • Market participants viewed the deal positively as a value-accretive transaction allowing Bayer to reduce leverage while maintaining operational ownership of a high-quality healthcare asset.
Summary
Apollo Global Management has agreed to acquire a minority stake in Bayer's long-acting reversible contraceptives business for €3bn, according to Bloomberg reporting. The transaction represents a significant strategic capital deployment that underscores Apollo's expanding role as a provider of large-scale financing solutions to multinational corporations seeking balance sheet optimization.
The newly created entity housing Bayer's contraceptives portfolio includes established brands such as Mirena, Kyleena, and Jaydess, which collectively generated approximately €1.4bn in annual revenue in 2025. Based on analyst valuations placing the business at around $6.5bn, Apollo's €3bn investment represents a substantial minority holding while allowing Bayer to retain full operational control. This structure—where the investor secures capital appreciation exposure while the original owner maintains day-to-day management—reflects a hybrid financing approach gaining traction among large corporates managing complex balance sheet challenges.
For Bayer, the capital raise serves a dual purpose within a broader strategic financial repositioning. The German healthcare and agriculture conglomerate continues to manage significant liabilities stemming from litigation over its Roundup herbicide, having increased litigation provisions to €11.8bn earlier this year and secured an $8bn bank financing facility to support settlement payments and debt maturities. The contraceptives business sale capitalizes on the company's portfolio of high-performing, stable-revenue assets to generate liquidity without sacrificing operational control or long-term upside participation.
The timing of the transaction follows Bayer's recent decision to separate its US glyphosate business into a standalone unit following a favorable US Supreme Court ruling on Roundup litigation, signaling a strategic effort to compartmentalize and address legacy liabilities. Market participants responded positively to the contraceptives deal, viewing it as an effective mechanism for Bayer to reduce financial leverage while retaining ownership of a defensive healthcare asset with predictable cash generation.
The transaction further illustrates Apollo's strategic pivot away from traditional leveraged buyouts toward providing bespoke capital solutions tailored to the financing needs of large corporates. This approach allows Apollo to deploy capital at scale while generating returns through structured equity or quasi-equity positions, rather than pursuing full acquisitions requiring operational overhauls.
The newly created entity housing Bayer's contraceptives portfolio includes established brands such as Mirena, Kyleena, and Jaydess, which collectively generated approximately €1.4bn in annual revenue in 2025. Based on analyst valuations placing the business at around $6.5bn, Apollo's €3bn investment represents a substantial minority holding while allowing Bayer to retain full operational control. This structure—where the investor secures capital appreciation exposure while the original owner maintains day-to-day management—reflects a hybrid financing approach gaining traction among large corporates managing complex balance sheet challenges.
For Bayer, the capital raise serves a dual purpose within a broader strategic financial repositioning. The German healthcare and agriculture conglomerate continues to manage significant liabilities stemming from litigation over its Roundup herbicide, having increased litigation provisions to €11.8bn earlier this year and secured an $8bn bank financing facility to support settlement payments and debt maturities. The contraceptives business sale capitalizes on the company's portfolio of high-performing, stable-revenue assets to generate liquidity without sacrificing operational control or long-term upside participation.
The timing of the transaction follows Bayer's recent decision to separate its US glyphosate business into a standalone unit following a favorable US Supreme Court ruling on Roundup litigation, signaling a strategic effort to compartmentalize and address legacy liabilities. Market participants responded positively to the contraceptives deal, viewing it as an effective mechanism for Bayer to reduce financial leverage while retaining ownership of a defensive healthcare asset with predictable cash generation.
The transaction further illustrates Apollo's strategic pivot away from traditional leveraged buyouts toward providing bespoke capital solutions tailored to the financing needs of large corporates. This approach allows Apollo to deploy capital at scale while generating returns through structured equity or quasi-equity positions, rather than pursuing full acquisitions requiring operational overhauls.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.